Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States
TAMPA, Fla., Jan. 16, 2025, 14:05 GMT-05
Concept-Medical
Read full article →
Category
Healthcare
This category brings together content related to healthcare, medicine, clinical research, healthcare services, medical devices, therapies and the development of solutions for the sector. Sector classification by EMSF Lisboa.
Cardiovascular Devices Market to Hit USD 110.39 Billion by 2029 with 7.3% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Jan. 16, 2025, 10:30 GMT-05
MarketsandMarkets
Read full article →
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
PLYMOUTH MEETING, Pa., Jan. 16, 2025, 08:07 GMT-05
NCCN
Read full article →
Aescuvest Capital Partners (ACP) Fund Empowers Visionary Healthtech Innovators for High Returns
MUNICH, Jan. 16, 2025, 06:29 GMT-05
Aescuvest-Healthtech
Read full article →
Acute Coronary Syndrome Market to Showcase a Significant Growth at a CAGR of 7.7% by 2034 | DelveInsight
LAS VEGAS, Jan. 15, 2025, 17:31 GMT-05
DelveInsight-Acute
Read full article →
Cerebrospinal Fluid (CSF) Management Market Set to Reach USD 3.8 Billion by 2031, Driven by Advancements in Medical Devices and Growing Neurological Disorder Prevalence - Market Research Intellect
LEWES, Del., Jan. 15, 2025, 10:45 GMT-05
MR-Intellect
Read full article →
San Raffaele Hospital (Milan, Italy): new, promising results from the first patients implanted with the spinal neurostimulator. A new, high-frequency spinal stimulation protocol gives hope for motor recovery and reduced muscular spasticity
MILAN, Jan. 15, 2025, 10:00 GMT-05
IRCCS-Ospedale-SanRa
Read full article →
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight
LAS VEGAS, Jan. 14, 2025, 17:31 GMT-05
DelveInsightBusiness
Read full article →
Clinical Informatics Market to Hit USD 563.18 Billion by 2030 with 16.0% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Jan. 14, 2025, 10:30 GMT-05
MARKETSANDMARKETS
Read full article →
BAIBYS™ Announces a Breakthrough in Fertility Treatment with a Newly CE Marked IVF System
TEL AVIV, Israel, Jan. 14, 2025, 09:30 GMT-05
BAIBYS-IVF-System
Read full article →
FDA Clears Ariceum Therapeutics' 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
BERLIN, Jan. 14, 2025, 09:00 GMT-05
Ariceum-Therapeutics
Read full article →
Oxygen Scavenger Market worth $4.32 billion by 2029 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Jan. 14, 2025, 06:30 GMT-05
MARKETSANDMARKETS
Read full article →
Enea TECH and Biomedical Foundation invests €15 million in Tethis to develop new diagnostic methods in oncology using liquid biopsy
ROME and MILAN, Jan. 14, 2025, 04:00 GMT-05
Enea-Tech-Biomedical
Read full article →
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM, Jan. 14, 2025, 21:51 GMT-05
BIOARCTIC-FDA
Read full article →
Exosome Therapies Market Poised for Explosive Growth During the Study Period (2025-2034) | DelveInsight
LAS VEGAS, Jan. 13, 2025, 17:31 GMT-05
DelveInsight-Business
Read full article →
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025, 09:05 GMT-05
Simcere-Abbvie
Read full article →
ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow
DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025, 09:00 GMT-05
CarlZeissMeditecAG
Read full article →
Q'Apel Medical Announces CE Mark Approval for Armadillo SelectFlex™ Neurovascular Access System
FREMONT, Calif., Jan. 13, 2025, 08:51 GMT-05
Q'Apel-Medical
Read full article →
Endo Launches New Peyronie's Disease Campaign: I Got Somebody
MALVERN, Pa., Jan. 13, 2025, 07:30 GMT-05
Endo-Peyronie-Disease
Read full article →
Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A
HELSINKI, Jan. 13, 2025, 06:30 GMT-05
Rappta-Therapeutics
Read full article →